Rapport Therapeutics advances RAP-219 Phase 3 epilepsy program in Q2 2026
The company reported enrollment in two Phase 3 focal seizure trials, a bipolar mania readout expected in October, and $436.1 million in cash as of June 30.
SEC filing
Latest
1 story